Össur hf: Q4 & FY 2022 Results - Conference Call Tuesday 31 January at 9:00 CET
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Össur hf: Q4 & FY 2022 Results - Conference Call Tuesday 31 January at 9:00 CET

Announcement no. 01/2023

17 January 2023

Conference call on Tuesday 31 January at 9:00 CET / 8:00 GMT / 3:00 ET

Össur will publish its financial results for Q4 & FY 2022 prior to market opening on Tuesday 31 January. That same day at 9:00 CET, Össur will host a conference call where Sveinn Sölvason, President and CEO, and Gudný Arna Sveinsdóttir, CFO, will present and discuss the results of the quarter and the full year. The conference call will be conducted in English.

A webcast can be followed on the Össur website: http://www.ossur.com/investors

To participate in the conference call, please click on this link: Össur Conference Call

Further information

Edda Lára Lúdvígsdóttir, Investor Relations Director, [email protected], +354 844 4759

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors

About Össur

Össur (Nasdaq Copenhagen: OSSR) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®. For over 50 years, Össur has had a strong purpose rooted in positively impacting people’s health and well-being. A recognized “Technology Pioneer”, Össur focuses on improving people’s mobility through the delivery of solutions that advance patient care. Significant investment in research and development has led to over 2,000 patents, award-winning designs, successful clinical outcomes, and steady growth. Össur is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women’s Empowerment Principles, and contributes to the UN Sustainable Development Goals. Össur operates globally and has around 4,000 employees. www.ossur.com

Nyheter om Embla Medical

Läses av andra just nu

Om aktien Embla Medical

Senaste nytt